The Nontuberculous Mycobacteria Market is forecast to grow from USD 2.0 billion in 2023 to USD 4.6 billion in 2033, at a compound annual growth rate of 8.8% across the seven major markets (7MM) . The US represents the largest market for NTM, with sales of USD 1.2 billion in 2023, equating to a market share of 62.1% across the 7MM. Japan, the second-largest market, was valued at USD 527.5 million in 2023, capturing 26.2% market share . The market growth is primarily driven by the launch of several novel pipeline agents, as well as the projected increase in diagnosed prevalent cases of NTM . Currently, the NTM market is dominated by off-label usage of highly genericized, broad-spectrum antibiotics, representing a significant unmet need for targeted therapies . For infectious disease specialists, pharmaceutical researchers, and healthcare administrators, the detailed report on Nontuberculous Mycobacteria Market provides essential benchmarking data.

There are several novel late-stage pipeline products in development specifically for the treatment of NTM infections expected to launch by 2033 . These include MannKind Corp's MNKD-101 (clofazimine), a novel formulation to be administered as an inhaled antibiotic for refractory NTM lung disease caused by Mycobacterium avium complex (MAC) . Paratek Pharmaceuticals' Nuzyra (omadacycline) is a novel tetracycline derivative, an aminomethylcycline antibiotic, in development for NTM lung disease caused by Mycobacterium abscessus complex (MABc) . Nobelpharma's NPC-26 (sargramostim) is an inhaled formulation of the recombinant protein being developed as a novel therapy for patients with NTM caused by MAC . Currently, there are no recombinant proteins being used to treat NTM infections within the 7MM . Key opinion leaders (KOLs) interviewed by GlobalData have highlighted the dire need for novel, effective NTM therapeutics, agreeing that MNKD-101 and Nuzyra appear promising .

Despite the anticipated launch of several innovative products, generic erosion will represent a barrier to growth over the forecast period. Products such as Arikayce (nebulized amikacin), Nuzyra, and Sirturo (bedaquiline) are expected to lose patent protection and become vulnerable to competition from generics . While the late-stage pipeline does address the need for novel, effective therapeutics, the current market domination by highly genericized antibiotics could end up limiting the uptake of these expensive, branded products . The NTM pipeline in the 7MM is rather limited, with only eight NTM pipeline products in active development across Phases I-III . The lack of effective therapeutics remains one of the biggest unmet needs within the NTM market . Nearly all drugs used to treat NTM infections are used off-label, and many are broad-spectrum antibiotics repurposed for NTM treatment . The pipeline agents set to enter the NTM market throughout the forecast period are all novel therapies, which could address this unmet need .

Simultaneously, the Mixed Reality in Healthcare market is experiencing exponential growth, with projections reaching USD 16.01 billion by 2030 at a CAGR of 62.8% . Mixed reality is revolutionizing medical training, surgery simulation, and patient care by blending real and virtual environments . The software segment dominates the market, driven by rising availability and accessibility of MR platforms . North America holds the largest share at 37.0%, while Asia-Pacific is the fastest-growing region . Key players include Microsoft, Philips, Siemens Healthineers, and GE Healthcare. The convergence of MR technology and infectious disease management presents opportunities for enhanced training in complex procedures . For healthcare administrators and technology developers, the market research available on Mixed Reality in Healthcare offers comprehensive guidance.